Navigation Links
InspireMD Hires Vice President of Corporate Development
Date:4/19/2013

TEL AVIV, Israel, April 19, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) said Gwen K. Bame has joined the Company as Vice President of Corporate Development, reporting directly to Alan Milinazzo , President and CEO.

    "This is a new position created to strengthen our executive team with a clear focus on executing strategic programs and partnerships designed to meet our ambitious global growth objectives," said Mr. Milinazzo.  "Gwen has the right blend of industry and management experience and we are delighted to welcome her to InspireMD."

    Ms. Bame's responsibilities will include identifying and negotiating in/out licensing agreements, analyzing strategic partnerships and structuring of joint ventures on a worldwide basis.

    Ms. Bame joined Covidien in 2009 upon its acquisition of Aspect Medical Systems, where she held various sales and marketing leadership positions during her tenure. She led significant market development programs directly and via strategic partnerships which drove adoption of the BIS technology.

    Prior to her time at Covidien, Ms. Bame spent 12 years with Boston Scientific in the cardiology business in sales, marketing and corporate accounts. During her career at BSC, she negotiated roughly $350 million in contracted business across multiple business units.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q.  Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
InspireMD Desk
Redington, Inc.
+1-212-926-1733
+1-203-222-7399
inspiremd@redingtoninc.com



'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Berman Joins InspireMD Board
2. InspireMD Postpones $40 Million Registered
3. InspireMD Reports 2012 Fiscal Year Results
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
6. InspireMD Appoints Dr. James Barry to Its Board of Directors
7. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
8. AFcell Medical Hires Chief Operating Officer
9. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
10. PI hires William Culpi as Engineering Chief - PI miCos USA Products by PI USA
11. InSoCal CONNECT Hires Technology Talent Executive Carol Caldwell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Poway, CA (PRWEB) , ... February 21, 2017 ... ... of its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, ... guidelines and utilizing the experience of both in-house personnel and consultants, VetStem constructed ...
(Date:2/21/2017)... Scientists From Two Companies to Accelerate Development ... ... STEER, creator of advanced materials platform technologies that effectively ... pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, today announced a ... company, on creating co-rotating twin screw extruder technology to ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017  This Report analyzes ... Software, Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific , ... Read the full report: http://www.reportlinker.com/p04707099-summary/view-report.html ... Annual estimates and forecasts ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... chest wall collapses in pre-term infants with respiratory distress, and assist surgeons ... $600,000 in funding through the ninth round of the University City Science ...
Breaking Biology Technology:
(Date:1/26/2017)... PANAMA CITY , Jan. 26, 2017  Crossmatch, ... today unveiled a new solution aimed at combatting fraud, ... The solution was introduced at the Action on Disaster ... a key meeting point for UN agencies and foreign ... Fraud, waste and abuse are a largely ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
Breaking Biology News(10 mins):